Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients

This publication has 28 references indexed in Scilit:

• Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
  Journal of Thoracic Oncology, 2020
• Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
  Nature Cancer, 2020
• Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
  Annals of Oncology, 2019
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types
  Nature Genetics, 2019
• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
  Science, 2018
• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
  New England Journal of Medicine, 2018
• Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
  Cancer Cell, 2018
• Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review
  Archives of Pathology & Laboratory Medicine, 2018
• Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
  Journal of Clinical Oncology, 2018
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
  The Lancet Oncology, 2015